Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.
Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
The Latest on: Gene therapy
- 'World's first gene therapy to halt most common cause of blindness' on February 19, 2019 at 5:22 am
Oxford researchers claim to have carried out the world's first gene therapy operation to halt age-related macular degeneration (AMD), the leading cause of untreatable blindness in the developed world. ... […]
- Gyroscope's gene therapy given to first dry AMD patient on February 19, 2019 at 4:50 am
UK biotech Gyroscope Therapeutics could have a mass market product on its hands if its new gene therapy for one of the most common form of blindness proves effective. The company has just dosed the fi... […]
- Gene therapy could treat rare brain disorder in unborn babies on February 18, 2019 at 2:00 pm
Doctors believe that for neurodevelopmental disorders, the best time to intervene with gene therapy may be before birth. Photograph: Alamy Scientists are developing a radical form of gene therapy that ... […]
- Surgeons carry out 'world first' gene therapy to tackle leading cause of sight loss in Britain on February 18, 2019 at 1:30 pm
Surgeons have carried out a world-first gene therapy operation to tackle the most common cause of sight loss in the UK. Age-related macular degeneration (AMD) causes the deterioration of cells in the ... […]
- British woman is first in the world to undergo gene therapy for most common form of blindness on February 18, 2019 at 11:05 am
A British woman has become the first person in the world to undergo gene therapy for the most common cause of sight loss. Surgeons at the John Radcliffe Hospital in Oxford inserted a synthetic gene in... […]
- Gene therapy firm to add 200 jobs, invest $60M in Durham county facility on February 18, 2019 at 9:29 am
RESEARCH TRIANGLE PARK – North Carolina’s global gene therapy leadership was boosted today with the announcement that AveXis, Inc., is doubling its planned workforce and investing $60 million more in ... […]
- Gene therapy company doubles plans for RTP jobs after receiving incentives on February 18, 2019 at 9:14 am
For the second time in less than a year, AveXis, a clinical-stage gene therapy company that makes treatments for spinal muscular atrophy, plans to create 200 jobs in Durham County. The new jobs would ... […]
- Gene therapy first to 'halt' most common cause of blindness on February 18, 2019 at 9:10 am
A woman from Oxford has become the first person in the world to have gene therapy to try to halt the most common form of blindness in the Western world. Surgeons injected a synthetic gene into the bac... […]
- Global Gene Therapy Research Report 2019: Technologies, Markets & Companies, 2017-2027 with Analysis of CRISPR-Cas9 and CAR-T Cell Therapies on February 18, 2019 at 3:28 am
DUBLIN, Feb. 18, 2019 /PRNewswire/ -- The "Gene Therapy - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. Gene therapy can be ... […]
- Once a ‘refugee,’ a gene therapy pioneer finds a renewed calling as the field advances on February 15, 2019 at 11:00 am
Gene therapy, now a pillar of biotechnology with the potential to cure deadly diseases, was once a cautionary tale of scientific brinkmanship. At the turn of the century, the once-promising idea of re... […]
via Google News and Bing News